|
1.
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Dudley ME, Wunderlich JR, Robbins PF, et
al: Cancer regression and autoimmunity in patients after clonal
repopulation with antitumor lymphocytes. Science. 298:850–854.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Dudley ME, Wunderlich JR, Yang JC, et al:
Adoptive cell transfer therapy following non-myeloablative but
lymphodepleting chemotherapy for the treatment of patients with
refractory meta-static melanoma. J Clin Oncol. 23:2346–2357. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Frangioni JV: In vivo near-infrared
fluorescence imaging. Curr Opin Chem Biol. 7:626–634. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
He X, Gao J, Gambhir SS and Cheng Z:
Near-infrared fluorescent nanoprobes for cancer molecular imaging:
status and challenges. Trends Mol Med. 16:574–583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kalchenko V, Shivtiel S, Malina V, et al:
Use of lipophilic near-infrared dye in whole-body optical imaging
of hematopoietic cell homing. J Biomed Opt. 11:0505072006.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Granot D, Addadi Y, Kalchenko V, Harmelin
A, Kunz-Schughart LA and Neeman M: In vivo imaging of the systemic
recruitment of fibroblasts to the angiogenic rim of ovarian
carcinoma tumors. Cancer Res. 67:9180–9189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hemmrich K, Meersch M, von Heimburg D and
Pallua N: Applicability of the dyes CFSE, CM-DiI and PKH26 for
tracking of human preadipocytes to evaluate adipose tissue
engineering. Cells Tissues Organs. 184:117–127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kikkawa YS and Pawlowski KS: Cochlear
neuronal tracing for frequency mapping with DiI, NeuroVue, and
Golgi methods. Acta Otolaryngol Suppl. 559:19–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Jiang J, Xu N, Wu C, et al: Treatment of
advanced gastric cancer by chemotherapy combined with autologous
cytokine-induced killer cells. Anticancer Res. 26:2237–2242.
2006.PubMed/NCBI
|
|
11.
|
Kim HM, Kang JS, Lim J, et al: Antitumor
activity of cytokine-induced killer cells in nude mouse xenograft
model. Arch Pharm Res. 32:781–787. 2009. View Article : Google Scholar
|
|
12.
|
Toh U, Fujii T, Mishima M, et al:
Conventional chemotherapy combined with the repetitive immune cell
transfer for patients with refractory advanced gastric cancer. Gan
To Kagaku Ryoho. 34:1931–1933. 2007.(In Japanese).
|
|
13.
|
Wongkajornsilp A, Sangsuriyong S, Hongeng
S, Waikakul S, Asavamongkolkul A and Huabprasert S: Effective
osteosarcoma cytolysis using cytokine-induced killer cells
pre-inoculated with tumor RNA-pulsed dendritic cells. J Orthop Res.
23:1460–1466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Yamagishi H, Ueda Y and Oka T: A case
report of immunotherapy on a patient with advanced gastric cancer
by adoptive transfer of OK-432-reactive HLA-matched allogeneic
lymphocytes. Cancer Immunol Immunother. 46:113–119. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Schmidt-Wolf IG, Lefterova P, Johnston V,
Huhn D, Blume KG and Negrin RS: Propagation of large numbers of T
cells with natural killer cell markers. Br J Haematol. 87:453–458.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Linn YC and Hui KM: Cytokine-induced
NK-like T cells: from bench to bedside. J Biomed Biotechnol.
2010:4357452010.PubMed/NCBI
|
|
17.
|
Linn YC, Lau LC and Hui KM: Generation of
cytokine-induced killer cells from leukaemic samples with in vitro
cytotoxicity against autologous and allogeneic leukaemic blasts. Br
J Haematol. 116:78–86. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Lopez RD, Waller EK, Lu PH and Negrin RS:
CD58/LFA-3 and IL-12 provided by activated monocytes are critical
in the in vitro expansion of CD56+ T cells. Cancer
Immunol Immunother. 49:629–640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Mehta BA, Schmidt-Wolf IG, Weissman IL and
Negrin RS: Two pathways of exocytosis of cytoplasmic granule
contents and target cell killing by cytokine-induced
CD3+ CD56+ killer cells. Blood. 86:3493–3499.
1995.PubMed/NCBI
|
|
20.
|
Koya RC, Mok S, Comin-Anduix B, et al:
Kinetic phases of distribution and tumor targeting by T cell
receptor engineered lymphocytes inducing robust antitumor
responses. Proc Natl Acad Sci USA. 107:14286–14291. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Shu CJ, Radu CG, Shelly SM, et al:
Quantitative PET reporter gene imaging of CD8+ T cells
specific for a melanoma-expressed self-antigen. Int Immunol.
21:155–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Butler MO, Lee JS, Ansen S, et al:
Long-lived antitumor CD8+ lymphocytes for adoptive
therapy generated using an artificial antigen-presenting cell. Clin
Cancer Res. 13:1857–1867. 2007.PubMed/NCBI
|
|
23.
|
Mackensen A, Meidenbauer N, Vogl S, Laumer
M, Berger J and Andreesen R: Phase I study of adoptive T-cell
therapy using antigen-specific CD8+ T cells for the
treatment of patients with metastatic melanoma. J Clin Oncol.
24:5060–5069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Yamaguchi Y, Ohshita A, Hironaka K, et al:
Adoptive immuno-therapy using autologous lymphocytes sensitized
with HLA class I-matched allogeneic tumor cells. Oncol Rep.
16:165–169. 2006.PubMed/NCBI
|
|
25.
|
Yee C, Thompson JA, Byrd D, et al:
Adoptive T cell therapy using antigen-specific CD8+ T
cell clones for the treatment of patients with metastatic melanoma:
in vivo persistence, migration, and antitumor effect of transferred
T cells. Proc Natl Acad Sci USA. 99:16168–16173. 2002.PubMed/NCBI
|
